inmd fact sheet april
TRANSCRIPT
-
8/7/2019 INMD Fact Sheet April
1/2
0
50
100
150
200
250
2006 2007 2008 2009 2010
DivisionalOverview:
TheAttainFertilityCentersdivision iscomprisedof14partner fertility centers with 66 locations and 87
physiciansandscientists that provide the full range of
fertility treatment services. The division also has 28
affiliate fertility centers with 66 locations that offer
IntegraMeds Attain IVF Program suite of fertility
treatmentfinancingsolutions.
The Vein Clinics division was formed on August 2007withthepurchaseofVeinClinicsofAmerica(VCA).The
VeinClinicsdivisionprovidesbusinessandmanagement
services to a network of 44 clinics across 14 states
specializing in the treatment of vein disease and
disorders.
IntegraMed also supports its operating divisions with
shared services that can be leveraged across the
operations. Included in the shared services
infrastructure are information systems, finance and
administration, human resources, legal services and
investorrelations.
LeadershipTeam:
JayHigham President/CEO:Architectofdiversificationstrategy,14yearswithINMD
AndrewMintz EVP/President,AttainFertilityCenteDan Doman President,VeinClinicsDivision leading
currentexpansionandorganicgrowthstrategy
TimSheehan VPFinance&InterimCFOScott Soifer EVP/CAO:Hasledhealthcaremarketing
andstrategyactivitiesforover18years
IntegraMedAmerica,Inc.Nasdaq:INMInvestorFactShee
April20
CorporateProfile:IntegraMedAmerica isa leader indeveloping,marketingandmanagingspecialtyoutpatienthealthcare facilitiwithacurrent focuson the fertility and vein care markets. IntegraMed supports its fertilityprovidernetwowithclinicalandbusinessinformationsystems,marketingandsales,facilitiesandoperationsmanagement,finan
and accounting, human resources, legal, risk management, quality assurance, and fertility treatment financprograms. IntegraMedprovidesthesameservicestosupportthegrowthand successofitsveinclinics.
InvestorInformation:NorbertoAjaorDavidCollins,Jaffoni&Collins,[email protected]
RecentEvents:January 2011: Acquired NorthwestCenter for ReproductSciencesandwillmergeitinto INMDs Seattleoperations.
February 2011: Announced 2010 Revenue Rose 12%$243M;NetIncomeRose5%to$4.7M
BusinessPerformance:
14%RevenueCAG
R
RevenueMixContributionMix
-
8/7/2019 INMD Fact Sheet April
2/2
MarketCap(3/31/11) $117M
Enterprise
Value
(3/31/11) $86
MEBITDA(ttm) $17M
EV/EBITDA(ttm) 5.
TrailingP/E(ttm) 25.
Price/Sales(ttm) 0.
Price/Book(mrq) 1.
SafeHarbor:Statementscontainedinthispresentationthatarenotbasedonhistoricalfact,includingstatementsconcerningfutureresults, performan
expectationsandexpansionofIntegraMedAmericaareforwardlookingstatements.Actualresultsmaydiffermateriallyfromthestatementsmadea
result of various factors including, but not limited to, the risks associated with the Companys ability to finance future growth; the loss of signific
businessservicescontract(s);profitabilityatfertilityandveincaredivisionsservicedbyIntegraMedAmerica;changesininsurancecoverage,governm
lawsandregulationsregardinghealthcareormanagedcarecontracting;andotherrisks, includingthose identifiedintheCompanysmostrecentFo
10Kand inotherdocuments filedbytheCompanywiththeU.S.SecuritiesandExchangeCommission. IntegraMeddoesnot assumeanyobligation
updateanyforwardlookingstatementsorotherinformationcontainedinthispresentation.
IntegraMedAmerica,Inc.Nasdaq:INMInvestorFactShee
April20
Revenues:
AttainFertilityCenters 182,443$ 166,135$
VeinClinics 60,726 50,625
TotalRevenues 243,169 216,760
OperatingIncome:
FertilityCenters 17,725 16,790
VeinClinics 3,491 4,100
TotalContribution 21,216 20,890
G&AExpenses 12,668 12,155
NetInterestExpense 695 910
IncomeBeforeIncomeTaxes 7,853 7,825
IncomeTaxes 3,128 3,331
NetIncome 4,725$ 4,494$
DilutedEPS 0.41$ 0.51$
DilutedShares 11,429 8,834
Cashandcashequivalents 50,183$ 28,865$
Totalcurrentassets 69,654$ 46,365$
Totalassets 148,655$ 124,309$
Longtermdebt 10,908$ 14,849$
TotalShareholders Equity 83,520$ 58,193$
(Allamountsinthousands,exceptpersharedata)
ValuationMeasures:
HistoricalStockPricesandVolume:
KeyTradingStatistics:
Dougherty&Co. BrooksONeal
PiperJaffrey MarkArnold
Sidoti&Co. Nick Halen
SingularResearch Frank DiLorenzo
Analyst
Coverage:
2010 2009
SummaryFinancialResults:
Recentprice(3/31/11)
52WeekLow
52WeekHigh
50DayMovingAverageAverageVolume(3m)
SharesOutstanding(12/31/10)
Beta
InstitutionalShareholder%
$9.90
$7.57
$11.04
$10.1820K
11.8M
0.6
31%